Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rick Strange who wrote (445)	2/3/1999 8:28:00 AM
From: RockDoc	Read Replies (1) of 1386

I think Rick has made a cogent comparison between the two companies. PARS really has a different core competency. That is the development of unique drugs from compounds that already exist (vs. enhancing "drugs" that already exist). Its best chance to break out is with the development of a blockbuster drug a la HU211. We have a safety net with Alrex, Lotemax and LE Tobra. None of us who bought in at this level will lose our shirts; we will all make modest returns on our investments. If HU211 hits, it's a whole other story, and one that we all would love to see! The only exception I see is the tamoxifen analog. It appears to be a promising enhancement of an already blockbuster drug. We are still many years away from knowing what it will do.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next